Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice

Autoimmunity

Volumn 48, Issue 4, 2015, Pages 259-266

  Ebihara, Shin ^a   Date, Fumiko ^a   Dong, Yupeng ^a   Ono, Masao ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

Author keywords

Animal model; Ankylosing spondylitis; Deep Koebner phenomenon; Interleukin 17; Psoriasis; Psoriatic arthritis

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CYTOKERATIN 16; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ACANTHOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANKYLOSING ENTHESITIS; ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; ENTHESITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOPATHOLOGY; HYPERKERATOSIS; MALE; MOUSE; NONHUMAN; PSORIASIS; PSORIASIS LIKE DERMATITIS; SWELLING; ANIMAL; ANKYLOSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; METABOLISM; PATHOLOGY; PREMEDICATION;

ANIMALS; ANKYLOSIS; ANTIBODIES, MONOCLONAL; DERMATITIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MICE; PREMEDICATION; PSORIASIS;

EID: 84929718360     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.976630     Document Type: Article

References (43)

1. Braun, J., and J. Sieper. (2007). Ankylosing spondylitis. Lancet. 369: 1379-1390
2. Ritchlin, C. (2007). Psoriatic disease-from skin to bone. Nat. Clin. Pract. Rheumatol. 3: 698-706
3. Braun, J., J. Brandt, J. Listing, et al. (2002). Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 359: 1187-1193
4. Davis Jr J. C., D. Van Der HeijDe, J. Braun, et al. (2003). Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis. Rheum. 8: 3230-3236
5. Van Den Bosch, F., E. Kruithof, D. Baeten, et al. (2000). Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. 9: 428-433
6. Mease, P. J., B. S. Goffe, J. Metz, et al. (2000). Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390
7. Haroon, N., R. D. Inman, T. J. Learch, et al. (2013). The impact of tumor necrosis factor a inhibitors on radiographic progression in ankylosing spondylitis. Arthritis. Rheum. 65: 2645-2654
8. Wendling, D., J. P. Cedoz, E. Racadot, and G. Dumoulin. (2007). Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74: 304-305
9. Mei, Y., F. Pan, J. Gao, et al. (2011). Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin. Rheumatol. 30: 269-273
10. Jandus, C., G. Bioley, J. P. Rivals, et al. (2008). Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritiDes. Arthritis Rheum. 58: 2307-2317
11. Shen, H., J. C. Goodall, and J. S. Hill Gaston. (2009). Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 60: 1647-1656
12. Kenna, T. J., S. I. Davidson, R. Duan, et al. (2012). Enrichment of circulating IL-17-secreting IL-23 receptor-positive gd T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 64: 1420-1429
13. NoorDenbos, T., N. Yeremenko, I. Gofita, et al. (2012). Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 64: 99-109
14. Appel, H., R. Maier, P. Wu, et al. (2011). Analysis of interleukin-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater releVance than the Th17 mediated adaptive immune response. Arthritis Res. Ther. 13: R95
15. Raychaudhuri, S. P., S. K. Raychaudhuri, and M. C. Genovese. (2012). IL-17 receptor and its functional significance in psoriatic arthritis. Mol. Cell. Biochem. 359: 419-429
16. Vegvari, A., Z. Szabo, S. Szanto, et al. (2009). The genetic background of ankylosing spondylitis. Joint Bone Spine 76: 623-628
17. Fitzgerald, O., and R. Winchester. (2009). Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res. Ther. 11: 214-222
18. Turner, M. J., M. L. Delay, S. Bai, et al. (2007). HLA-B27 upregulation causes accumulation of misfolDed heavy chains and correlates with the magnituDe of the unfolDed protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 56: 215-223
19. DeLay, M. L., M. J. Turner, E. I. Klenk, et al. (2009). HLA-B27 misfolding and the unfolDed protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis. Rheum. 60: 2633-2643
20. Bowes, J., and A. Barton. (2010). The genetics of psoriatic arthritis: lessons from genome-wiDe association studies. Discov. Med. 10: 177-183
21. Papp, K. A., R. G. Langley, B. Sigurgeirsson, et al. (2013). Efficacy and safety of secukinumab in the treatment of moDerate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br. J. Dermatol. 168: 412-421
22. McInnes, I. B., J. Sieper, J. Braun, et al. (2014). Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moDerate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73: 349-356
23. Baeten, D., X. Baraliakos, J. Braun, et al. (2013). Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 382: 1705-1713
24. Oishi, H., T. Miyazaki, S. Mizuki, et al. (2005). Accelerating effect of an MRL gene locus on the severity and onset of arthropathy in DBA/1 mice. Arthritis. Rheum. 52: 959-966
25. Corthay, A., A. S. Hansson, and R. Holmdahl. (2000). T lymphocytes are not required for the spontaneous Development of entheseal ossification leading to marginal ankylosis in the DBA/1 mouse. Arthritis. Rheum. 43: 844-851
26. Lories, R. J., I. Derese, C. De Bari, and F. P. Luyten. (2007). EviDence for uncoupling of inflammation and joint remoDeling in a mouse moDel of spondylarthritis. Arthritis. Rheum. 56: 489-497
27. Lories, R. J., P. Matthys, K. De Vlam, et al. (2004). Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a moDel of psoriatic arthritis. Ann. Rheum. Dis. 63: 595-598
28. Leigh, I. M., H. Navsaria, P. E. Purkis, et al. (1995). Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br. J. Dermatol. 133: 501-511
29. Eckert, R. L., A. M. Broome, M. Ruse, et al. (2004). S100 proteins in the epiDermis. J. Invest. Dermatol. 123: 23-33
30. Wilson, N. J., K. Boniface, J. R. Chan, et al. (2007). Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957
31. Ballow, M. (2011). The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorDers. J. Allergy. Clin. Immunol. 127: 315-23
32. Lin, A. M., C. J. Rubin, R. Khandpur, et al. (2011). Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187: 490-500
33. Res, P. C., G. Piskin, O. J. De Boer, et al. (2010). Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS. One. 5: e14108
34. Crellin, N. K., S. Trifari, C. D. Kaplan, et al. (2010). Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J. Exp. Med. 207: 281-290
35. McGonagle, D., Z. Ash, L. Dickie, et al. (2011). The early phase of psoriatic arthritis. Ann. Rheum. Dis. 70: i71-i76
36. Semprini, S., F. Capon, A. Tacconelli, et al. (2002). EviDence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. Hum. Genet. 111: 310-313
37. Pattison, E., B. J. Harrison, C. E. Griffiths, et al. (2008). Environmental risk factors for the Development of psoriatic arthritis: results from a case-control study. Ann. Rheum. Dis. 67: 672-676
38. Stankler, L. (1969). An experimental investigation on the site of skin damage inducing the Koebner reaction in psoriasis. Br. J. Dermatol. 81: 534-535
39. Iwakura, Y., H. Ishigame, S. Saijo, and S. Nakae. (2011). Functional specialization of interleukin-17 family members. Immunity 34: 149-162
40. Charles, P., M. J. Elliott, D. Davis, et al. (1999). Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-Alpha therapy in rheumatoid arthritis. J. Immunol. 163: 1521-1528
41. Ma, H. L., S. Liang, J. Li, et al. (2008). IL-22 is required for Th17 cell-mediated pathology in a mouse moDel of psoriasis-like skin inflammation. J. Clin. Invest. 118: 597-607
42. Smith, E., M. A. Stark, A. Zarbock, et al. (2008). IL-17A inhibits the expansion of IL-17A-producing T cells in mice through shortloop inhibition via IL-17 receptor. J. Immunol. 181: 1357-1364
43. Algood, H. M., S. S. Allen, M. K. Washington, et al. (2009). Regulation of gastric B cell recruitment is DepenDent on IL-17 receptor a signaling in a moDel of chronic bacterial infection. J. Immunol. 183: 5837-5846